27 March 2024
EMA/50717/2024
EMEA/H/C/005675

**Public statement**

# Vaxzevria[1] (COVID 19 Vaccine (ChAdOx1 S [recombinant]))

## Withdrawal of the marketing authorisation in the European Union

On 27 March 2024, the European Commission withdrew the marketing authorisation for Vaxzevria (COVID 19 Vaccine (ChAdOx1 S [recombinant])) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, AstraZeneca AB, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Vaxzevria was granted conditional marketing authorisation in the EU on 29 January 2021 for active immunisation against coronavirus disease 2019 (COVID-19). The conditional marketing authorisation was switched to a standard marketing authorization, valid for 5 years, on 31 October 2022.

The European Public Assessment Report (EPAR) for Vaxzevria will be updated to indicate that the marketing authorisation is no longer valid.

[1] Previously known as COVID-19 Vaccine AstraZeneca

**Official address** Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
**Address for visits and deliveries** Refer to www.ema.europa.eu/how-to-find-us
**Send us a question** Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union